Pfizer and Allergan--which both confirmed on Thursday that they're in "friendly" deal talks--may be intrigued with the prospect of a tie-up. But politicians gung-ho about stopping tax inversions? Not so much.
The FDA is trying to learn more about virtual clinical trials, the bring-your-own-device (BYOD) model of provisioning and other aspects of today's tech-enabled research environment. The regulator has set up a docket to gather feedback on how researchers are using technology and what barriers are stopping more widespread adoption.
GlaxoSmithKline and Pfizer have both been working on incorporating continuous manufacturing into their production networks.
Pfizer--searching for deals in advance of a potential split-up later this decade--has approached Allergan about an acquisition, Allergan said in a statement on Thursday. The drugmakers are in "preliminary friendly discussions," Allergan said, though they won't necessarily amount to a combination.
The Wall Street Journal broke the news last night that Pfizer and Allergan have had some early discussions about merging into a $330 billion behemoth. Neither company is talking, but the irresistible conclusion remains that a deal just might make sense.
Pfizer says it'll "reconsider" its investment in a psoriasis indication for Xeljanz, recently rejected by the FDA, after it meets with the agency.
A two-year shortage of saline solutions has had the attention of hospitals that have had to sometimes ration a product they once took for granted. But it has now caught the attention of some U.S. senators who are asking the FTC to look into whether saline producers have using it to unreasonably jack up prices.
Earlier this month, the FDA slapped down Pfizer's Xeljanz as a treatment for moderate to severe cases of plaque psoriasis. And that could be the end of the line for the med in that indication, execs said Tuesday.
After a strong first half, Pfizer's vaccine unit didn't let up in the third quarter, continuing on an upward trajectory as growing Prevnar 13 sales continued to propel the unit forward.
On the company's third-quarter earnings call, Pfizer Chairman and CEO Ian Read fended off repeated questions on a new structure for the company that could be spurred by tax changes while letting a key executive paint a broad picture of how cash stashed abroad may play a part in any decision.